MOLECULAR CANCER THERAPEUTICS
The Journal of Cancer Drug Discovery & Preclinical Development

AN OFFICIAL JOURNAL OF THE American Association for Cancer Research

Editor-in-Chief
Beverly A. Teicher

Deputy Editors
Yubin Kang
Akash Patnaik
Puja Sapra
Paul Workman

Senior Editors
Timothy P. Cripe
Susan M. Galbraith
Iqbal S. Grewal
Peter J. Houghton
Candace S. Johnson
Ricky W. Johnstone
Razelle Kurzrock
David G. Kirsch
John S. Lazo
Joel Morris
Brion W. Murray
Dario Neri
Seth M. Pollack
Martine F. Roussel
Marco Ruella
Peter Senter
Louis F. Stancato

Associate Editors
Richard W. Davis IV

Associate Journal Manager
Crystal Cheepudom

Editorial Staff
Nageena Laing
Meredith A. Kahn

Special Content Manager
Chris Vesci

Senior Production Editor
Jennifer L. Harper

Editorial Board
Robert T. Abraham
Rajesh Agarwal
Adriana Albini
Kari Alitalo
Suresh V. Ambudkar
Paul A. Andrews
Avi Ashkenazi
James E. Audia
André S. Bachmann
Raffaele Baffa
Rebecca G. Bagley

Albert S. Baldwin, Jr.
David Bears
Darell D. Bigner
Michael L. Bittner
Thomas F. Bumol
Robert M. Campbell
David A. Cheresh
James G. Christensen
Steve R. Coats
Barbara A. Conley
Robert A. Copeland
Sayed S. Daoud
Marcia I. Dawson
William A. Denny
Paul Dent
Channing J. Der
Vishva M. Dixit
Ethan Dmitrovsky
Suzanne A. Eccles
Heinz-Herbert Fiebig
William D. Figg, Sr.
Paul B. Fisher
Antonio Fojo
Arthur E. Frankel
Lori Friedman
Stephen V. Frye
Simone Fulda
Ram N. Ganapathi
Michelle D. Garrett

(continued on next page)
Editorial Board (Continued)

Kathy Gately
Andreas J. Gescher
David A. Gewirtz
Amato J. Giaccia
William H. Gmeiner
I. David Goldman
Michael M. Gottesman
Lorraine J. Gudas
Yusuf A. Hannun
Stephen B. Howell
Donna Huryn
Rakesh K. Jain
Peter A. Jones
Craig T. Jordan
Juliane M. Jürgensmeier
Robert S. Kerbel
Andrew S. Kraft
Donald W. Kufe
Michihiko Kuwano
Zihai Li
Mary M. Mader
Daruka Mahadevan
Sanjay V. Malhotra
Sridhar Mani
Lawrence D. Mayer
David J. McConnell
Frank McCormick
Giovanni Melillo
Ira Mellman
Paul S. Mischel
Brett P. Monia
Nouri Neamati
Robert A. Newman
Barry R. O’Keefe
Pier Paolo Pandolfi
Ira Pastan
Steven R. Patierno
Maurizio Pellecchia
Gail D. Lewis Phillips
Andrew Phillips
Yves Pommier
C. Patrick Reynolds
Edward A. Sausville
Jeffrey Settleman
Shivendra V. Singh
David B. Solit
Michael B. Sporn
Pavel Strop
Bin Tean Teh
Carter Van Waes
Kristina Vuori
Shaomeng Wang
David J. Waxman
Tai Wai Wong
Amy E. Wright
Jingwu Xie
Leigh S. Zawel
Yuesheng Zhang

Trusted and Timely
Publication of Scientific Discoveries

AACR'S ESTEEMED JOURNAL COLLECTION

CANCER DISCOVERY
The essential information source to serve the diverse professional community in cancer science and medicine
Impact Factor: 26.370

Cancer Epidemiology, Biomarkers & Prevention
Translating science to populations
Impact Factor: 5.057

Cancer Immunology Research
Supporting the fight against cancer and the immune system
Impact Factor: 8.619

Cancer Prevention Research
The foremost of prevention science
Impact Factor: 3.866

Cancer Research
The foundational cancer journal driving transformative science
Impact Factor: 8.378

Clinical Cancer Research
The journal of clinical and translational research
Impact Factor: 8.911

Molecular Cancer Research
Defining the molecular basis of malignancy and progression
Impact Factor: 4.484

Molecular Cancer Therapeutics
The journal of cancer drug discovery and preclinical development
Impact Factor: 4.856

Subscribe Today!
PubSales@AACR.org
Learn more at AACRJournals.org

American Association for Cancer Research
FINDING CURES TOGETHER®
Scope

Molecular Cancer Therapeutics strives to be the top choice for publishing the best science in the discovery and preclinical development of novel therapeutic agents for oncology, preclinical studies of approved therapeutics, mechanisms of drug action, mechanisms of drug resistance, biomarkers of drug response, novel models and technologies, and occasional drug toxicity mechanisms. While the Journal’s main focus is on small molecule and protein drugs, other molecular entities may be considered.

Molecular Cancer Therapeutics is abstracted and/or indexed in Current Contents/Clinical Medicine, MEDLINE, Science Citation Index, Scopus, and Web of Science.

Submission of Manuscripts

Online manuscript submission is welcomed at http://mct.msubmit.net. Before submitting a manuscript, please read the Instructions for Authors, which is available from the Journal’s home page at http://mct.aacrjournals.org.

Publication Charges

Beginning with manuscripts submitted January 1, 2016 or after, articles will be published with the understanding that the author(s) will pay both a publication fee plus a color figure handling fee. Please see the Instructions for Authors, which are available from the Journal’s home page at http://mct.aacrjournals.org.

Scope

Molecular Cancer Therapeutics strives to be the top choice for publishing the best science in the discovery and preclinical development of novel therapeutic agents for oncology, preclinical studies of approved therapeutics, mechanisms of drug action, mechanisms of drug resistance, biomarkers of drug response, novel models and technologies, and occasional drug toxicity mechanisms. While the Journal’s main focus is on small molecule and protein drugs, other molecular entities may be considered.

Molecular Cancer Therapeutics is abstracted and/or indexed in Current Contents/Clinical Medicine, MEDLINE, Science Citation Index, Scopus, and Web of Science.

Submission of Manuscripts

Online manuscript submission is welcomed at http://mct.msubmit.net. Before submitting a manuscript, please read the Instructions for Authors, which is available from the Journal’s home page at http://mct.aacrjournals.org.

Publication Charges

Beginning with manuscripts submitted January 1, 2016 or after, articles will be published with the understanding that the author(s) will pay both a publication fee plus a color figure handling fee. Please see the Instructions for Authors, which are available from the Journal’s home page at http://mct.aacrjournals.org.

Subscription Information

Nonmember Individuals

Subscriptions include print version with online access. Contacts listed below are for nonmember individual subscriptions.

USA and Rest of World (excluding Japan)
American Association for Cancer Research, 615 Chestnut Street, Philadelphia, PA 19106; 1-855-744-4667; pubsales@aacr.org

Japan
e-support@maruzen.co.jp; journal@kinokuniya.co.jp; usaco@usaco.co.jp

International print subscriptions include cost of surface mail. Expedited mailing is available. Contact the American Association for Cancer Research for rates.

Site Licenses

For information about institutional site licenses, contact pubsales@aacr.org.

AACR Members

AACR members may opt to receive either a print subscription with online access to content or an online-only subscription. Contact membership@aacr.org or visit the membership page at www.aacr.org for more information.

Single Issue Sales

Subject to their availability, single or back issues may be purchased for $60 (U.S.) or $65 (outside the U.S.) each. The cost must be prepaid. Contact pubsales@aacr.org.

Claims

One-time claims for missing issues made within 120 days of the issue’s publication will be honored, subject to availability. No credit or refund will be given if an issue is out of print at the time of claim.

AACR Members

membership@aacr.org

Nonmembers and Institutions

pubsales@aacr.org

Advertising Information

For information about advertising in AACR journals, contact Pharmaceutical Media Inc., 30 East 33rd St., 4th Floor, New York, NY 10016; 212-904-0360; Dsimone@pminy.com

Copyright and Permissions

Content printed in or disseminated by Molecular Cancer Therapeutics is protected by copyright. Authors who wish to publish material in Molecular Cancer Therapeutics must formally transfer copyright to the AACR. All authors must sign copyright transfer forms before the AACR can proceed with publication.

To read the complete AACR Copyright and Permissions Policy, visit http://aacrjournals.org/content/authors/copyright-permissions-and-access.